Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome - A Randomized Controlled Cross-Over Trial

Lauche, Romy; Janzen, Anke; Lüdtke, Rainer; Cramer, Holger; Dobos, Gustav; Langhorst, Jost

doi:10.1159/000398790

Cited by 16 publications

(8 citation statements)

References 43 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A group difference of 83 points on the IBS‐SSS total score has been shown to represent a considerable self‐reported improvement . Assuming a standard deviation of 103.8, based on a former trial with IBS patients, a two‐sided, level 5% t test requires a total of 26 patients per study group in order to detect a respective group difference with a statistical power of 80%. To account for the potential loss of statistical power from the withdrawal of up to 10% of participants, the trial aimed to recruit a total of at least 58 patients.…”

Section: Methodsmentioning

confidence: 99%

Randomised clinical trial: yoga vs a low‐FODMAP diet in patients with irritable bowel syndrome

Schumann

Langhorst

Dobos

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Irritable bowel syndrome is the most frequent gastrointestinal disorder. It is assumed that lifestyle interventions might be a rational treatment approach. Aim To examine the effect of a yoga‐based intervention vs a low‐FODMAP diet on patients with irritable bowel syndrome. Methods Fifty‐nine patients with irritable bowel syndrome undertook a single‐blind, randomised controlled trial involving yoga or a low‐FODMAP diet for 12 weeks. Patients in the yoga group received two sessions weekly, while patients in the low‐FODMAP group received a total of three sessions of nutritional counselling. The primary outcome was a change in gastrointestinal symptoms (IBS‐SSS). Secondary outcomes explored changes in quality of life (IBS‐QOL), health (SF‐36), perceived stress (CPSS, PSQ), body awareness (BAQ), body responsiveness (BRS) and safety of the interventions. Outcomes were examined in weeks 12 and 24 by assessors “blinded” to patients’ group allocation. Results No statistically significant difference was found between the intervention groups, with regard to IBS‐SSS score, at either 12 (Δ = 31.80; 95%CI = −11.90, 75.50; P = .151) or 24 weeks (Δ = 33.41; 95%CI = −4.21, 71.04; P = .081). Within‐group comparisons showed statistically significant effects for yoga and low‐FODMAP diet at both 12 and 24 weeks (all P < .001). Comparable within‐group effects occurred for the other outcomes. One patient in each intervention group experienced serious adverse events (P = 1.00) and another, also in each group, experienced nonserious adverse events (P = 1.00). Conclusions Patients with irritable bowel syndrome might benefit from yoga and a low‐FODMAP diet, as both groups showed a reduction in gastrointestinal symptoms. More research on the underlying mechanisms of both interventions is warranted, as well as exploration of potential benefits from their combined use.

show abstract

Section: Methodsmentioning

confidence: 99%

Randomised clinical trial: yoga vs a low‐FODMAP diet in patients with irritable bowel syndrome

Schumann

Langhorst

Dobos

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…It consists of three single questions that allow three different answers and a 100-point VAS on which 0 reflects the worst and 100 the best possible condition. All questionnaires have been used in German language before [26, 27]. In addition, stool frequency was quantified before and at the end of the study.…”

Section: Methodsmentioning

confidence: 99%

Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome

Barmeyer

Schümann

Meyer

et al. 2016

Int J Colorectal Dis

View full text Add to dashboard Cite

PurposeIrritable bowel syndrome (IBS) is common but therapies are unsatisfactory. Food is often suspected as cause by patients, but diagnostic procedures, apart from allergy testing, are limited. Based on the hypothesis of non-celiac wheat sensitivity (WS) in a subgroup of IBS patients, we tested the long-term response to a gluten-free diet (GFD) and investigated HLA-DQ2 or -DQ8 expression as a diagnostic marker for WS in diarrhea-dominant (IBS-D) and mixed-type IBS (IBS-M).MethodsThe response to a GFD served as reference test for WS and HLA-DQ2/8 expression was determined as index test. Patients were classified as responders if they reported complete or considerable relief of IBS symptoms on at least 75 % of weeks over a 4-month period of gluten-free diet. Established questionnaires (IBS-Quality of Life (IBS-QoL), IBS Symptom Severity Scale (IBS-SSS), European Quality of Life-5 Dimensions (EQ-5D)) were used for secondary outcome measures.ResultsThirty-five patients finished the study. Of these, 12 (34 %) were responders and classified as having WS (95 % CI 21–51 %). HLA-DQ2/8 expression had a specificity of 52 % (95 % CI 33–71 %) and sensitivity of 25 % (95 % CI 8–54 %) for WS. Responders showed improvement in quality of life and symptom scores. At 1-year follow-up, all responders and 55 % of non-responders were still on GFD and reported symptom relief.ConclusionUsing strict criteria as recommended for IBS studies, about one third of patients with IBS-D or IBS-M are wheat sensitive, with a similar proportion in both IBS types. Expression of HLA-DQ2/8 is not useful as diagnostic marker for WS. Long-term adherence to a GFD is high and can sustain symptomatic improvement.Electronic supplementary materialThe online version of this article (doi:10.1007/s00384-016-2663-x) contains supplementary material, which is available to authorized users.

show abstract

“…Using this definition, 57.9% of patients responded to treatment with humic acids and 36.8% of patients responded to treatment with placebo. Other studies using the same definition for a response have reported responses to treatment in between 43.9% and 81% of patients, and responses to placebo in between 18.9% and 46% of patients [50][51][52].…”

Section: Discussionmentioning

confidence: 96%

Humic Acids in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome: Results from A Randomised Controlled Trial

Haufe¹,

Gammel²,

Schiefke

2021

BJSTR

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder. There is no definitive treatment for IBS and all medications implemented in its treatment have concerns of tolerability and safety associated with their use. The WH67®-R-2012 study was a randomised, double-blind, placebo-controlled clinical trial comparing the effect of humic acids versus placebo in patients with diarrhoeapredominant IBS (IBS-D). The primary endpoint of the study was an improvement of IBS symptoms measured with the irritable bowel syndrome severity scoring system (IBS-SSS). Secondary endpoints were improvements in quality of life (IBS-QOL), the Bristol Stool Form Scale (BSFS), and in the short form 36 (SF-36). Forty-six patients were recruited to participate in the study. No adverse events were reported and no patient discontinued the study. There was no main effect for treatment (F=1.56, p=0.221), centre (F=1.71, p=0.201), or sex (F=2.47, p=0.127). We defined a response to treatment as an improvement of at least 50 points on the IBS-SSS. 57.9% of patients responded to treatment with humic acids and 36.8% of patients responded to treatment with placebo (χ 2 =1. 69, p=0.194). In patients receiving humic acids, women were more likely to be responders than men (71.4% vs. 20.0%, χ 2 =4.00, p=0.045). This was the first study testing the effect of humic acids as a potential treatment for IBS-D. No adverse events were reported, reflecting the very good tolerability of humic acids. If proven efficacious in a larger study, humic acids could represent a novel treatment option, which is much-needed for IBS-D.

show abstract

Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome - A Randomized Controlled Cross-Over Trial

Cited by 16 publications

References 43 publications

Randomised clinical trial: yoga vs a low‐FODMAP diet in patients with irritable bowel syndrome

Randomised clinical trial: yoga vs a low‐FODMAP diet in patients with irritable bowel syndrome

Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome

Humic Acids in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome: Results from A Randomised Controlled Trial

Contact Info

Product

Resources

About